- Argenx SE's ARGX Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint.
- The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP. Patients were heavily pretreated.
- A higher proportion of patients with chronic ITP receiving VYVGART (17/78; 21.8%) than placebo (2/40; 5%) achieved a sustained platelet response.
- Vyvgart-treated patients had a statistically significant benefit compared to placebo on a cumulative number of weeks where platelet counts were at least 50x109/L and sustained platelet response in the overall population.
- Numerically fewer WHO-classified bleeding events occurred in treated patients throughout the trial, but the difference from placebo was not statistically significant.
- Ten Vyvgart-treated patients switched to a biweekly dosing schedule after achieving platelet counts of 100x109/L for three out of four consecutive visits, compared to one placebo patient.
- Nine of the ten treated patients achieved a sustained platelet response.
- Vyvgart was well-tolerated, and the observed safety and tolerability profile were consistent with previous clinical trials.
- The Phase 3 ADVANCE trial is the first of two registrational trials being conducted as part of the ongoing ITP development program.
- ADVANCE-SC is evaluating subcutaneous efgartigimod for the treatment of primary ITP. Topline data are expected in Q1 of 2023.
- Price Action: ARGX shares are up 9.53% at $320.84 during the market session on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.